Geron (NASDAQ:GERN) was upgraded by research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.
A number of other research analysts have also issued reports on the stock. BTIG Research started coverage on shares of Geron in a research note on Tuesday, February 12th. They set a “buy” rating and a $4.00 price target on the stock. B. Riley raised shares of Geron from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $1.50 to $3.25 in a report on Thursday, January 31st. ValuEngine raised shares of Geron from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Finally, Zacks Investment Research raised shares of Geron from a “strong sell” rating to a “hold” rating in a report on Tuesday, December 4th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $4.09.
Shares of Geron stock opened at $1.67 on Friday. Geron has a 52-week low of $0.95 and a 52-week high of $6.99. The stock has a market cap of $309.41 million, a PE ratio of -10.44 and a beta of 2.94.
Geron (NASDAQ:GERN) last issued its quarterly earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05). Geron had a negative net margin of 2,534.43% and a negative return on equity of 17.61%. The business had revenue of $0.38 million for the quarter, compared to analyst estimates of $0.22 million. Research analysts predict that Geron will post -0.34 EPS for the current year.
A number of hedge funds have recently added to or reduced their stakes in the stock. FMR LLC lifted its holdings in shares of Geron by 158.4% in the fourth quarter. FMR LLC now owns 15,536,850 shares of the biopharmaceutical company’s stock valued at $15,537,000 after purchasing an additional 9,523,953 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of Geron by 242.5% in the fourth quarter. Millennium Management LLC now owns 736,307 shares of the biopharmaceutical company’s stock valued at $736,000 after purchasing an additional 1,253,007 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Geron by 7.9% in the fourth quarter. BlackRock Inc. now owns 15,038,176 shares of the biopharmaceutical company’s stock valued at $15,037,000 after purchasing an additional 1,102,419 shares in the last quarter. Two Sigma Investments LP purchased a new stake in shares of Geron in the fourth quarter valued at about $985,000. Finally, Vanguard Group Inc lifted its holdings in shares of Geron by 8.2% in the third quarter. Vanguard Group Inc now owns 8,751,607 shares of the biopharmaceutical company’s stock valued at $15,403,000 after purchasing an additional 661,446 shares in the last quarter. 33.56% of the stock is currently owned by hedge funds and other institutional investors.
Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses.
Further Reading: How does new data get added to a blockchain?
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.